The bioresorbable scaffolds (BRSs), while providing a temporary vessel scaffold, gradually resorbed free of any caging, eventually restoring the vessel wall physiology and vasomotion, has been heralded as the fourth revolution in interventional cardiology. Currently, there are several BRSs available with different compositions (e.g., polymer or metallic alloy), strengths, and weaknesses in China. The NeoVas™ scaffold (Lepu Medical, Beijing, China) is a balloon expandable BRSs, and consists of four components: a poly-L-lactic acid platform, poly-D, L-lactide acid polymer, antiproliferative drug sirolimus (15.3 µg/mm scaffold lengths), and radiopaque markers at the ends (Figure 10.5.1). The mean strut thickness of the NeoVas scaffold is 170 µm, which consists of a backbone thickness of 160 µm and polymer thickness of 10 µm. The device crossing profile is 1.40 mm and 6-French catheter compatible. The kinetic release data indicated that approximately 75% of the drug releases within 1 month after scaffold implantation. The NeoVas scaffold has to be kept at a temperature between 0 and 10°C to ensure device stability and a shelf life of up to 1 year.,
Erasmus MC: University Medical Center Rotterdam

Han, Y. (Yaling), & Zhang, Y.-J. (Yao-Jun). (2017). NeoVas™ bioresorbable coronary scaffold system. In Bioresorbable Scaffolds: From Basic Concept to Clinical Applications. doi:10.1201/9781315380629